In addition, the presence of vascular development genes (VEGF and thrombospondin48) within BA-associated ESGs suggests potential resistance mechanisms to anti-PD1 treatments, a finding requiring further investigation. This evidence concerns the gene VEGFA and breast angiosarcoma.